GlassScriptPhysician profile
Stacey A Coyle
NPI 1316585474
$14,618.02
in general payments reported to CMS, 2019-2025
55 companies · $2,643 in 2025
The $2,643 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,473 · 2022: $2,132 · 2023: $4,121 · 2024: $3,249 · 2025: $2,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,888 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,888.34 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.70 | 2021-2025 | |
| Novo Nordisk INC | $1,626.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,097.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $886.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $879.47 | 2021-2025 | |
| Amgen INC. | $697.95 | 2021-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.40 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $485.58 | 2021-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $426.01 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.73 | 2021-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $398.28 | 2021-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $352.64 | 2022-2025 | Proclaim |
| Novartis Pharmaceuticals Corporation | $337.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $299.94 | 2021-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Bayer Healthcare Pharmaceuticals INC. | $276.46 | 2021-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.